|

Erlotinib Hydrochloride Clinical Trials

1 actively recruiting trial across 1 location

Also known as: CP 358, CP-358, CP358, Cp-358,774, OSI 774 +3 more

Pipeline

Phase 2: 1

Top Sponsors

  • Mayo Clinic1

Indications

  • Stage IVC Lip and Oral Cavity Cancer AJCC v81
  • Recurrent Oral Cavity Carcinoma1
  • Metastatic Oral Cavity Carcinoma1
  • Cancer1

Rochester, Minnesota1 trial

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

Mayo Clinic in Rochester

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.